Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Beta3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure

NCT02775539 is registered in ClinicalTrials.gov with Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III as lead sponsor.

NCT NCT02775539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02775539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Beta3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure
Lead sponsor
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2016
Completion date
June 30, 2019
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, mirabegron, pulmonary hypertension, pulmonary vascular resistance abnormality